H. Xiong

Concurrent TP53 mutation adversely impact the efficacy of crizotinib in ROS1-rearranged lung cancer patients.

Jun Zhao, X. Ai, F. Yu, 2019, Journal of Clinical Oncology.

Pharmacogenetic meta‐analysis suggests that atrasentan is an organic anion transport protein C substrate

R. Holley-Shanks, R. Carr, D. Katz, 2004 .